Obstructive Sleep Apnea (OSA) Drugs Market: By Drugs (CNS Stimulants, Benzodiazepines, Non-Benzodiazepines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography

Obstructive Sleep Apnea (OSA) Drugs Market size was valued at USD x million in 2022 and is expected to grow at a CAGR of x% from 2023-2029. obstructive sleep apnea (OSA) drugs market report gives comprehensive outlook on obstructive sleep apnea (OSA) drugs across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report on global obstructive sleep apnea (OSA) drugs market gives historical, current, and future market sizes (US$ Mn) on the basis of drugs, distribution channel, and region. This report studies global obstructive sleep apnea (OSA) drugs market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global obstructive sleep apnea (OSA) drugs market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global obstructive sleep apnea (OSA) drugs market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the global obstructive sleep apnea (OSA) drugs market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global obstructive sleep apnea (OSA) drugs.  

Global Obstructive Sleep Apnea (OSA) Drugs Market:

The global obstructive sleep apnea (OSA) drugs market estimated to be valued US$ 1121.3 Mn in 2018 and poised to grow at significant CAGR over 2019-2025 owing to rise in prevalence of obstructive sleep apnea and its comorbidities coupled with growing geriatric population. For instance, currently 1.5 million in the United Kingdom are living with obstructive sleeping apnea and around 667,000 (45 percent) of the 1.5 million people estimated to be living with obstructive sleep apnea in UK have the moderate to severe forms of disorders. However, only 330,000 are receiving the treatment they need. Moreover, development and launch of new products in the market and focus on generic version of OSA products fuels the growth of the obstructive sleep apnea (OSA) drugs in the market. However, side effects of the OSA drugs over devices and non-availability of regular medical reimbursement policies for sleep apnea are expected to hamper the growth of the market.  

Rise in Prevalence of Obstructive Sleep Apnea and its Comorbidities

 The prevalence rate of obstructive sleep apnea (OSA) is increasing rapidly across the globe which increases risk of road traffic, work-related accidents, cardiovascular diseases and strokes. As per the National Commission on Sleeping Disorders Research, globally about 38,000 deaths are accounting annually owing to the cardiovascular problems associated with sleep apnea. OSA is also correlated with heart failure which is 12-16% more prevalent in OSA patients. It has also been observed that approximately 60-70% of OSA patients are obese. Increasing prevalence of Obstructive Sleep Apnea is associated with number of cardiac and metabolic diseases. However, awareness, diagnosis, and treatment of Obstructive Sleep Apnea could offer significant savings to the patient  

North America Leads the Market with Highest Share in Global Obstructive Sleep Apnea (OSA) Drugs Market

North America accounted for larger revenue share in global obstructive sleep apnea (OSA) drugs market with significant CAGR and is expected to grow with highest CAGR during the forecast period owing to favorable reimbursement policies in the region and entry of market players with the generics for obstructive sleep apnea drugs in the region. Moreover, presence of prominent players in the region and awareness campaigns by the market players in the region are expected to enhance the growth of the market. Europe and Asia Pacific are expected to show robust growth in the market over the forecasted period.  

Key players profiles in the global obstructive sleep apnea (OSA) drugs market include:

• Biogen Inc. (United States)
• Pfizer (United States)
• Johnson & Johnson (United States)
• Eli Lilly (United States)
• Merck (United States)
• AstraZeneca (United Kingdom)
• Novartis (Switzerland)
• Jazz Pharmaceuticals (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)

Global obstructive sleep apnea (OSA) drugs market is surging owing to development and launch of innovative products in different markets to expand the portfolio and strengthen their position in the market. For instance, in 2016, Mylan N.V. announced that the U.S. launch of Armodafinil tablets, 50 mg, 150 mg, 250 mg, a generic version of Cephlon’s Nuvigil®. Mylan received final approval for USFDA for its ANDA and was awarded 180 days of marketing exclusivity for the above mentioned strengths. For instance, RespireRx Pharmaceuticals Inc. has developed an oral capsule drug product that is being tested for clinical efficacy in patients with Obstructive Sleep Apnea (OSA).   Key Findings of the Report:  

• Global obstructive sleep apnea (OSA) drugs market expanding at significant CAGR over 2018 to 2025 owing to rise in prevalence of obstructive sleep apnea and its comorbidities
• Based on drugs, CNS stimulants accounted for larger market revenue share in 2018 and projected gain market revenue share over the forecast period
• Players focusing on innovation of newer products and collaboration strategies to retain market position in global obstructive sleep apnea (OSA) drugs market

  Key Features of the Report:  

• The report provides granular level information about the market size, regional market share, historic market (2014-2018) and forecast (2019-2025)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

  Detailed Segmentation   By Drugs

• CNS Stimulants
• Benzodiazepines
• Non-Benzodiazepines

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

  Geography North America

• US
• Canada

Europe

• Germany
• France
• UK
• Italy
• Spain
• Russia
• Poland
• Rest of Europe

Asia-Pacific

• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America

Middle East and Africa (MEA)

• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

---

Location

GEOGRAPHY